The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") on behalf of those who ...

The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. . Shareholders who purchased shares ...

William Blair lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a market ...

Fintel reports that on March 10, 2025, Guggenheim downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy ...

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal ...

Detailed price information for Neumora Therapeutics Inc (NMRA-Q) from The Globe and Mail including charting and trades.

William Blair downgraded Neumora Therapeutics (NMRA) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: ...

Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to ...

While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...